2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Carbonic Anhydrase

Carbonic Anhydrase

Carbonate dehydratase

Carbonic Anhydrase

Related Products

PDF 0.73 MB

Carbonic anhydrase (CA) is a zinc-containing enzyme that catalyzes the reversible hydration of carbon dioxide: CO2 + H2O ⇋ HCO3- + H+. Eight genetically distinct carbonic anhydrase enzyme families (α-, β-, γ- δ-, ζ-, η-, θ- and ι- CAs) were described to date. Carbonic anhydrases are involved in numerous physiological and pathological processes. Many of them are important therapeutic targets with the potential to be inhibited to treat a range of disorders including oedema, glaucoma, obesity, cancer, epilepsy, and osteoporosis.

The carbonic anhydrase reaction is involved in many physiological and pathological processes, including respiration and transport of CO2 and bicarbonate between metabolizing tissues and lungs; pH and CO2 homeostasis; electrolyte secretion in various tissues and organs; biosynthetic reactions (such as gluconeogenesis, lipogenesis, and ureagenesis); bone resorption; calcification; and tumorigenicity. α-CAs are Zn2+ metalloproteins expressed in animals, vertebrates, prokaryotes, fungi, algae, protozoa, and plants. Sixteen mammalian α-CA isoforms are known to be involved in many diseases such as glaucoma, edema, epilepsy, obesity, hypoxic tumors, neuropathic pain, arthritis, neurodegeneration, etc.

Carbonic Anhydrase Isoform Specific Products:

Carbonic Anhydrase Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-149301
    hCAIX-IN-18
    		Inhibitor 98.52%
    hCAIX-IN-18 (compound 30) is an inhibitor of carbonic anhydrase (CA), with Kis of 3.5 nM, 9.4 nM, 43.0 nM and 8.2 nM for hCAI, hCAII, hCAIX, hCAXII, respectively. hCAIX-IN-18 can be used for cancer research.
    hCAIX-IN-18
  • HY-155391
    hCA/Wnt/β-catenin-IN-1
    		Inhibitor 99.96%
    hCA/Wnt/β-catenin-IN-1 (Compd 15) is an inhibitor of hCA (Ki: 33.6, 24.1, 6.8 nM for hCA II, hCA IX, hCA XII). hCA/Wnt/β-catenin-IN-1 reduces P-gp activity. hCA/Wnt/β-catenin-IN-1 also inhibits Wnt/β-catenin signaling pathway. hCA/Wnt/β-catenin-IN-1 inhibits cancer cell viability, including the NCI/ADR-RES DOX-resistant cell line.
    hCA/Wnt/β-catenin-IN-1
  • HY-D2345
    GZ22-4
    		99.37%
    GZ22-4 is a near-infrared (NIR) fluorescent probe. GZ22-4 shows high affinity for carbonic anhydrase IX (CAIX), with a Kd of 0.2 nM. GZ22-4 can be used for the research of visualize CAIX-positive tumors.
    GZ22-4
  • HY-B1471
    Fluorometholone acetate
    		Inhibitor 98.54%
    Fluorometholone acetate is a synthetic glucocorticoid corticosteroid and a corticosteroid ester. Fluorometholone acetate potently inhibits carbonic anhydrase (CA) with IC50s of 2.18 μM and 17.5 μM for hCA-I and hCA-II, respectively. Fluorometholone acetate has anti-inflammatory effect and has the potential for external ocular inflammation research.
    Fluorometholone acetate
  • HY-110234
    Topiramate D12
    		Inhibitor 99.90%
    Topiramate D12 (McN 4853 D12) is a deuterium labeled Topiramate. Topiramate is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase.
    Topiramate D12
  • HY-B1056
    Procodazole
    		Inhibitor 99.73%
    Procodazole is an orally active enhancer and a non-specific active immune protector against viral and bacterial infections. Procodazole also exhibits antiparasitic activity. In addition, Procodazole is a carbonic anhydrase inhibitor with antitumor activity.
    Procodazole
  • HY-138365
    EMAC10101d
    		Inhibitor 99.77%
    EMAC10101d is a potent and selective toward hCA II inhibitor, with a Ki of 8.1 nM.
    EMAC10101d
  • HY-123179
    Mefruside
    		Inhibitor 99.9%
    Mefruside is an orally active diuretic and has a mild hypotensive effect. Mefruside inhibits the synthesis of urea in an isolated rat liver perfusion model. Mefruside can be used in studies of oedema and hypertension.
    Mefruside
  • HY-151916
    Enpp/Carbonic anhydrase-IN-1
    		Inhibitor 99.57%
    Enpp/Carbonic anhydrase-IN-1 (compound 1e) is a potent Enpp and carbonic anhydrase inhibitor with IC50s of 1.36, 1.35, 3.00, 0.88, 1.02 μM for NPP1, NPP2, NPP3, CA-II, CA-IX respectively. Enpp/Carbonic anhydrase-IN-1 shows antiproliferative activity for cancer cells and low cytotoxic against normal cells. Enpp/Carbonic anhydrase-IN-1 induces Apoptosis.
    Enpp/Carbonic anhydrase-IN-1
  • HY-B0109
    Dorzolamide
    		Inhibitor
    Dorzolamide (L671152) is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity.
    Dorzolamide
  • HY-B0124A
    Zonisamide sodium
    		Inhibitor
    Zonisamide (AD 810) sodium is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide sodium exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide sodium also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide sodium can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy.
    Zonisamide sodium
  • HY-B0122S
    Topiramate-13C6
    		Inhibitor 99.67%
    Topiramate-13C6 (McN 4853-13C6) is the 13C labeled isotope of Topiramate (HY-B0122). Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase.
    Topiramate-<sup>13</sup>C<sub>6</sub>
  • HY-N1393R
    2-Methoxybenzoic acid (Standard)
    2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether) (Standard) is the analytical standard of 2-Methoxybenzoic acid (HY-N1393). 2-Methoxybenzoic acid is a natural compound with potential salicylate-like effect. 2-Methoxybenzoic acid inhibits carbonic anhydrase activity, elevates intraplatelet cyclic guanosine monophosphate level, and suppresses cytosolic phospholipase A2 phosphorylation. 2-Methoxybenzoic acid suppresses platelet reactivity, including decreased spreading, retraction, and aggregation in platelets. 2-Methoxybenzoic acid ameliorates arterial thrombosis in a dose-dependent manner without affecting normal hemostasis in mice. 2-Methoxybenzoic acid can be used for the research of arterial thrombosis.
    2-Methoxybenzoic acid (Standard)
  • HY-169964
    TSPO/Carbonic Anhydrase Modulator 1
    		Modulator
    TSPO/Carbonic Anhydrase Modulator 1 (Compound 3) is a dual modulator for mitochondrial translocator protein and Carbonic Anhydrase with a Ki of 1.340 μM for TSPO and a KA of 10.7 μM for CA VII. TSPO/Carbonic Anhydrase Modulator 1 promotes the production of neurosteroid, increases BDNF gene expression, exhibits neuroprotective efficacy.
    TSPO/Carbonic Anhydrase Modulator 1
  • HY-B0782S1
    Acetazolamide-13C2,d3
    		Inhibitor
    Acetazolamide-13C2,d3 is the 13C- and deuterium labeled Acetazolamide. Acetazolamide is a carbonic anhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX. Diuretic effects.
    Acetazolamide-<sup>13</sup>C<sub>2</sub>,d<sub>3</sub>
  • HY-B0283A
    Acipimox sodium
    Acipimox (K-9321) sodium, a nicotinic acid analogue, is an antilipolytic compound. Acipimox sodium stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity.
    Acipimox sodium
  • HY-174232
    EGFR/CA-IX-IN-1
    		Inhibitor
    EGFR/CA-IX-IN-1 (Compound 14) is a dual inhibitor against epidermal growth factor receptor (EGFR) and carbonic anhydrase IX (CA-IX) with IC50 values of 5.92 nM and 63 nM, respectively. EGFR/CA-IX-IN-1 shows strong cytotoxicity against breast cancer cells (MDA-MB-231, MCF-7) with IC50 values of 5.78 μM and 8.05 μM, respectively. EGFR/CA-IX-IN-1 inhibits the catalytic activity of CA-IX, up-regulates BAX/Bcl-2, activates caspases, and arrests the cell cycle at the G1 phase. EGFR/CA-IX-IN-1 is promising for research of breast cancer.
    EGFR/CA-IX-IN-1
  • HY-152140
    hCAII-IN-8
    		Inhibitor 99.41%
    hCAII-IN-8, an amide, is a highly selective carbonic anhydrase (CA) inhibitor with an IC50 value of 0.18 μM against hCA II.
    hCAII-IN-8
  • HY-161322
    hCAXII-IN-9
    		Inhibitor
    hCAXII-IN-9 (Compound 3I) is a selective inhibitor of hCAXII with Ki values of 28 nM, 7192.6 nM, 188.6 nM, and >100000 nM for hCAXII, hCAI, hCAII, and hCAIX, respectively. hCAXII-IN-9 can be utilized in antitumor research.
    hCAXII-IN-9
  • HY-120321
    DSR-71167
    		Inhibitor
    DSR-71167 is an orally active mineralocorticoid receptor (MR) antagonist with an IC50 of 0.26 μM. DSR-71167 exhibits weak carbonic anhydrase (CA) inhibitory activity with an IC50 of 19 μM. DSR-71167 can dose-dependently increase urinary sodium excretion in rat models and has a very low risk of hyperkalemia in potassium-loading rat models. DSR-71167 lowers systolic blood pressure in hypertensive rat models. DSR-71167 can be used for research on hypertension and heart failure.
    DSR-71167
Cat. No. Product Name / Synonyms Species Source
Carbonic Anhydrase Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.